Literature DB >> 15723146

Legionella pneumonia and serum procalcitonin.

Laura Franzin1, Daniela Cabodi.   

Abstract

Procalcitonin is a specific marker of severe bacterial infections with systemic inflammation. Quantitative evaluation of serum procalcitonin was performed in 140 patients with Legionella pneumonia. Positive values (>0.5 ng/mL) were found in 57.1% of the subjects. The positive sample rate was higher in early sera (73.9% in the first week) and decreased progressively. Mean values and the positive sample rate (69.8%) were higher in sera collected in the first 2 weeks of disease. Procalcitonin was positive in 86.7% of legionellosis cases confirmed by culture and mean positive values were significantly higher (P < 0.001) than those of culture-negative subjects. We conclude that procalcitonin can represent a useful prognostic marker for severe suspected Legionella pneumonia in the first 2 weeks of disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15723146     DOI: 10.1007/s00284-004-4360-1

Source DB:  PubMed          Journal:  Curr Microbiol        ISSN: 0343-8651            Impact factor:   2.188


  17 in total

1.  Procalcitonin as a parameter of disease severity and risk of mortality in patients with Plasmodium falciparum malaria.

Authors:  C B Chiwakata; C Manegold; L Bönicke; I Waase; C Jülch; M Dietrich
Journal:  J Infect Dis       Date:  2001-03-01       Impact factor: 5.226

Review 2.  Procalcitonin as a marker of bacterial infection.

Authors:  D Gendrel; C Bohuon
Journal:  Pediatr Infect Dis J       Date:  2000-08       Impact factor: 2.129

3.  New outbreak of legionnaires' disease in the United Kingdom.

Authors:  Carol Joseph
Journal:  BMJ       Date:  2002-08-17

4.  Diagnosis of Legionella infection.

Authors:  David R Murdoch
Journal:  Clin Infect Dis       Date:  2002-12-12       Impact factor: 9.079

5.  Guidelines for prevention of nosocomial pneumonia. Centers for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1997-01-03

6.  Discrimination of infectious and noninfectious causes of early acute respiratory distress syndrome by procalcitonin.

Authors:  F M Brunkhorst; O K Eberhard; R Brunkhorst
Journal:  Crit Care Med       Date:  1999-10       Impact factor: 7.598

Review 7.  Legionnaires' disease.

Authors:  P H Edelstein
Journal:  Clin Infect Dis       Date:  1993-06       Impact factor: 9.079

8.  Trends in legionnaires disease, 1980-1998: declining mortality and new patterns of diagnosis.

Authors:  Andrea L Benin; Robert F Benson; Richard E Besser
Journal:  Clin Infect Dis       Date:  2002-10-14       Impact factor: 9.079

Review 9.  Legionella and Legionnaires' disease: 25 years of investigation.

Authors:  Barry S Fields; Robert F Benson; Richard E Besser
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

10.  Procalcitonin-a new diagnostic tool in complications following liver transplantation.

Authors:  E R Kuse; I Langefeld; K Jaeger; W R Külpmann
Journal:  Intensive Care Med       Date:  2000-03       Impact factor: 17.440

View more
  5 in total

1.  Prognostic value of procalcitonin in Legionella pneumonia.

Authors:  J Haeuptle; R Zaborsky; R Fiumefreddo; A Trampuz; I Steffen; R Frei; M Christ-Crain; B Müller; P Schuetz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-08-02       Impact factor: 3.267

Review 2.  Legionnaires' disease: clinical differentiation from typical and other atypical pneumonias.

Authors:  Burke A Cunha
Journal:  Infect Dis Clin North Am       Date:  2010-03       Impact factor: 5.982

Review 3.  Advances in community-acquired pneumonia.

Authors:  Barbara Jones; Grant Waterer
Journal:  Ther Adv Infect Dis       Date:  2020-11-06

Review 4.  Biomarkers: a definite plus in pneumonia.

Authors:  Hanssa Summah; Jie-Ming Qu
Journal:  Mediators Inflamm       Date:  2009       Impact factor: 4.711

5.  Severe Legionella pneumonia: rapid presumptive clinical diagnosis with Winthrop-University Hospital's weighted point score system (modified).

Authors:  Burke A Cunha
Journal:  Heart Lung       Date:  2008 Jul-Aug       Impact factor: 2.210

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.